Short-term Efficiency and Tolerance of Ketoprofen and Methylprednisolone in Acute Sciatica: A Randomized Trial.
Adult
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Double-Blind Method
Female
Glucocorticoids
/ therapeutic use
Humans
Intervertebral Disc Displacement
/ complications
Ketoprofen
/ therapeutic use
Lumbar Vertebrae
Male
Methylprednisolone
/ therapeutic use
Middle Aged
Pain Management
/ methods
Sciatica
/ drug therapy
Treatment Outcome
Discogenic Compression
Glucocorticoids
Nonsteroidal Anti-inflammatory Drugs
Sciatica
Therapy
Journal
Pain medicine (Malden, Mass.)
ISSN: 1526-4637
Titre abrégé: Pain Med
Pays: England
ID NLM: 100894201
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
pubmed:
24
12
2018
medline:
10
7
2020
entrez:
22
12
2018
Statut:
ppublish
Résumé
Although anti-inflammatory drugs are commonly used in acute discogenic sciatica, data regarding their efficacy are scarce and controversial. We compared the efficacy and safety of intravenous ketoprofen and methylprednisolone with placebo in sciatica. Multicenter, double-blinded randomized controlled trial. Patients with confirmed discogenic acute sciatica, without neurologic deficit, were randomized into three arms. Besides standard-of-care analgesic therapy, they received intravenous injections of methylprednisolone (60 mg/d) or ketoprofen (200 mg/d) or placebo for five days. The primary outcome was leg pain over five days. Secondary outcomes were clinical responses at days 3 and 5, lumbar pain, Straight Leg Raise Test and lumbar flexion index, analgesic consumption, realization of lumbar spine injections, and surgery during the study period. Fifty-four patients were randomized, and 50 completed the study. In patients admitted to the hospital for pain control with acute lumbar radicular pain due to intervertebral disc herniation and receiving an oral analgesic protocol including paracetamol, nefopam, tramadol, and morphine, there was no additional analgesic effect seen between groups. There was no significant difference in leg pain between the three groups over the study period. In the methylprednisolone group, however, we observed a higher rate of clinically relevant responses at day 3. No difference was observed on other secondary efficacy outcomes and safety. No significant difference in leg pain was observed between groups. However, there was a higher proportion of patients relieved with intravenous methylprednisolone at day 3, compared with ketoprofen or placebo.
Identifiants
pubmed: 30576555
pii: 5256994
doi: 10.1093/pm/pny252
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Glucocorticoids
0
Ketoprofen
90Y4QC304K
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1294-1299Informations de copyright
© 2018 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.